On-Demand CME Videos
Liberating Patients from Prurigo Nodularis One Itch at a Time: Online CME Activity
This activity was recorded at the 2023 Winter Clinical Dermatology Conference-Hawaii on January 16, 2023.
CME Satellite Symposium:
Liberating Patients from Prurigo Nodularis One Itch at a Time
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
February 10, 2023
February 10, 2024
At the completion of this activity, participants should be better able to:
Cite strategies to diagnose patients with prurigo nodularis
Overview on how biologics target the prurigo nodularis disease pathway
Examine the clinical trial data for emerging therapies to treat prurigo nodularis
Identify strategies to incorporate emerging therapies for prurigo into clinical practice
Raj Chovatiya, MD, PhD
Assistant Professor, Director of Center for Eczema and Itch
Northwestern University Feinberg School of Medicine
Brian Kim, MD
Mount Sinai Icahn School of Medicine
New York, NY
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Consultant: AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, L’Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi, and UCB
Speakers’ Bureau or Honoraria: AbbVie, Arcutis, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi, and UCB
Grant/Research Support: LEO Pharma, Cara Therapeutics
Consultant: AbbView, Almirall, BMS, Pfizer, Regeneron, IncyteSano
Intellectual Property Rights: JAK Inhibitors for Itch
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.